GlassScriptPhysician profile
Christopher N Marshall
NPI 1700197266
$9,139.99
in general payments reported to CMS, 2019-2025
36 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $781 · 2021: $823 · 2022: $1,413 · 2023: $1,850 · 2024: $1,374 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,608 · Education: $94.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,608.46 |
| Education | $94.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,006.40 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Otsuka America Pharmaceutical, INC. | $794.43 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $696.03 | 2019-2025 | Veltassa |
| Amgen INC. | $673.83 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Mallinckrodt Hospital Products INC. | $615.00 | 2020-2025 | Acthar, Terlivaz |
| Novartis Pharmaceuticals Corporation | $612.34 | 2019-2025 | |
| Horizon Therapeutics Plc | $578.12 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $536.21 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $397.84 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $348.59 | 2021-2025 | |
| Novo Nordisk INC | $314.28 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.24 | 2022-2025 | Jardiance |
| Akebia Therapeutics INC | $268.12 | 2019-2025 | Vafseo |
| Mallinckrodt Enterprises LLC | $230.06 | 2019 | |
| Alexion Pharmaceuticals, INC. | $227.45 | 2019-2025 | Ultomiris |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $198.50 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $187.67 | 2021-2025 | Benlysta, Jesduvroq |
| Opko Pharmaceuticals, LLC | $184.25 | 2019-2023 | Rayaldee |
| Daiichi Sankyo INC. | $158.39 | 2020-2024 | Injectafer |
| Fresenius USA Marketing, INC. | $116.77 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $83.90 | 2022-2025 | Tarpeyo |
| Shield Therapeutics INC | $80.69 | 2023-2025 | Accrufer |
| Shire North American Group INC | $78.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.84 | 2020-2024 | Gattex |
| Ardelyx, INC. | $65.38 | 2023-2024 | Ibsrela |
| Lilly USA, LLC | $49.75 | 2024-2025 | Jardiance |
| Scpharmaceuticals INC. | $41.36 | 2025 | |
| Argenx US, INC. | $37.61 | 2022-2023 | Vyvgart |
| Rockwell Medical, INC. | $36.28 | 2020 | |
| Apellis Pharmaceuticals, INC. | $34.17 | 2025 | Empaveli |
| Outset Medical INC | $23.67 | 2024 | |
| Baxter Healthcare | $22.09 | 2024 | Renal - Pd |
| Cycle Pharmaceuticals INC | $20.42 | 2025 | Venxxiva |
| Teleflex LLC | $18.87 | 2025 | Arrow |
| Genentech USA, INC. | $18.07 | 2025 | Gazyva |
| Bard Peripheral Vascular, INC. | $16.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.